Recently, the 240 MeV Superconducting Proton Cyclotron developed by Hefei CAS Ion Medical and Technical Devices Co., Ltd.(HFCIM) achieved beam extraction, marking another technological breakthrough of domestic medical superconducting proton cyclotron in Hefei.

The 240 MeV superconducting proton cyclotron provides higher energy and current to create full coverage of proton radiation therapy for tumors, and to meet technological needs of FLASH therapy.

The beam energy extracted from this cyclotron is 243 MeV; the current on extraction target meets the requirement of Environmental Impact Assessment; the extracted efficiency of deflector is more than 75%, with 120kV/cm stable operation; the zero evaporation cryogenic system was applied to develop the superconducting magnet; main magnet field runs to 4.5 Tesla. Beam intensity modulation is offered for proton radiotherapy by vertical deflector in center region; the fast turn-off time is less than 100 μs. The cyclotron has a diameter of 3 meters and weighs less than 75 tons.

The performance indicators of the 240 MeV superconducting proton cyclotron have reached the world’s leading level and the cyclotron will be used as a domestic alternative for imported counterparts. Furthermore, the cyclotron is under mass production. The second one will soon enter the beam commissioning stage, and the third cyclotron is under manufacturing process.

As a new medical superconducting proton cyclotron, the 240 MeV superconducting proton cyclotron is developed from the SC200 superconducting proton cyclotron, which is developed and manufactured by HFCIM and has been operating stably for over 2 years. In addition, HFCIM has produced a high intensity proton cyclotron with an energy of 14 MeV; the company also has the capability to produce 300 MeV multi-particle superconducting cyclotron and 10-20 MeV high intensity cyclotron.

Relying on the innovation platform of Hefei Comprehensive National Science Centre, based on the key technologies and innovation team of the large scientific device, HFCIM is committed to the independent research and development of domestic superconducting cyclotron therapy system and promoting the clinical application research of medical-science-industrial combination. The independently-developed superconducting cyclotron therapy system CAPRO-X1 by HFCIM is going to move to the medical verification base in 2023 for commissioning, testing and clinical trials. HFCIM will continuously commit itself to breaking through key technologies of high-end medical devices and systems, hence make contribution to the health industry of Anhui Province and the whole nation.